TrialThe Lancet. Oncology2023

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial.

Dominik Dytfeld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.